



SOCIETA' ITALIANA DI CANCEROLOGIA

53rd Annual Meeting of the
Italian Cancer Society

Back to the Future

Translating cancer research
from bedside to bench and back

Turin, 19 – 22 October 2011



SOCIETA' ITALIANA DI CANCEROLOGIA

53rd Annual Meeting of the Italian Cancer Society

SIC SCIENTIFIC BOARD

President

Alfredo Fusco (*"Federico II" University, Naples, Italy*)

President Elect

Riccardo Dolcetti (*CRO-IRCCS, National Cancer Institute, Aviano, Pordenone, Italy*)

Board

Anna Bagnato (*Regina Elena National Cancer Institute, Rome, Italy*)

Vincenzo Bronte (*University of Verona, Italy*)

Alfredo Budillon (*National Cancer Institute "G. Pascale", Naples, Italy*)

Maurizio D'Incalci (*"Mario Negri" Institute for Pharmacological Research, Milan, Italy*)

Silvia Giordano (*Institute for Cancer Research and Treatment, University of Turin, Candiolo, Italy*)

Salvatore Pece (*IFOM-IEO Campus, University of Milan, Italy*)

Katia Scotlandi (*Orthopaedic Rizzoli Institute, Bologna, Italy*)

Gabriella Sozzi (*IRCCS National Cancer Institute, Milan, Italy*)

Stefania Tommasi (*National Cancer Centre "Giovanni Paolo II", Bari, Italy*)

Past President

Adriana Albini (*IRCCS MultiMedica, Sesto San Giovanni-Milan, Italy*)

SCIENTIFIC AND ORGANIZING COMMITTEE

Scientific Coordinator

Silvia Giordano (*Institute for Cancer Research and Treatment, University of Turin, Candiolo, Italy*)

Local Scientific Committee

Massimo Aglietta (*Institute for Cancer Research and Treatment, University of Turin, Candiolo, Italy*)

Maria Felice Brizzi (*University of Turin, Italy*)

Federico Bussolino (*Institute for Cancer Research and Treatment, University of Turin, Candiolo, Italy*)

Paolo M. Comoglio (*Institute for Cancer Research and Treatment, University of Turin, Candiolo, Italy*)

Federica Di Nicolantonio (*Institute for Cancer Research and Treatment, University of Turin, Candiolo, Italy*)

Maria Flavia Di Renzo (*Institute for Cancer Research and Treatment, University of Turin, Candiolo, Italy*)

Filippo Montemurro (*Institute for Cancer Research and Treatment, University of Turin, Candiolo, Italy*)

Wanda Piacibello (*Institute for Cancer Research and Treatment, University of Turin, Candiolo, Italy*)

Luca Tamagnone (*Institute for Cancer Research and Treatment, University of Turin, Candiolo, Italy*)

ORGANIZING SECRETARIAT

Adria Congrex Srl

Via Sassonia, 30 – 47922 Rimini RN

Ph. +39 0541 305811

Fax +39 0541 305842

E-mail: sic2011@adriacongrex.it

Web site: www.adriacongrex.it/sic2011

SIC SECRETARIAT

Società Italiana di Cancerologia

Via G. Venezian, 1 – 20133 Milan

Ph. +39 02 2666895

Fax +39 02 2664342

E-mail: sic@istitutotumori.mi.it

Web site: www.cancerologia.it

Back to the Future

Translating cancer research
from bedside to bench and back

Turin, 19 – 22 October 2011

FACULTY

Massimo Aglietta

Institute for Cancer Research and Treatment, University of Turin, Candiolo, Italy

Adriana Albini

IRCCS MultiMedica, Sesto San Giovanni-Milan, Italy

Anna Bagnato

Regina Elena National Cancer Institute, Rome, Italy

Mariano Barbacid

Spanish National Cancer Research Centre, Madrid, Spain

Giovanni Blandino

Regina Elena National Cancer Institute, Rome, Italy

Mario Boccardo

University of Turin, Italy

Maria Felice Brizzi

University of Turin, Italy

Alfredo Budillon

National Cancer Institute "G. Pascale", Naples, Italy

Federico Bussolino

Institute for Cancer Research and Treatment, University of Turin, Candiolo, Italy

George Adrian Calin

MD Anderson Cancer Center, Houston, TX, USA

Amedeo Columbano

University of Cagliari, Cagliari, Italy

Paolo M. Comoglio

Institute for Cancer Research and Treatment, University of Turin, Candiolo, Italy

Maurizio D'Incalci

"Mario Negri" Institute for Pharmacological Research, Milan, Italy

Donatella Del Bufalo

Regina Elena National Cancer Institute, Rome, Italy

Federica Di Nicolantonio

Institute for Cancer Research and Treatment, University of Turin, Candiolo, Italy

Maria Flavia Di Renzo

Institute for Cancer Research and Treatment, University of Turin, Candiolo, Italy

Riccardo Dolcetti

CRO-IRCCS, National Cancer Institute, Aviano, Pordenone, Italy

Tommaso Dragani

IRCCS National Cancer Institute, Milan, Italy

Guido Forni

University of Turin, Italy

Alfredo Fusco

"Federico II" University, Naples, Italy

Adrianus Henricus Maria Geurts van Kessel

Radboud University Nijmegen, Nijmegen, The Netherlands

Raffaella Giavazzi

"Mario Negri" Institute for Pharmacological Research, Milan, Italy

Silvia Giordano

Institute for Cancer Research and Treatment, University of Turin, Candiolo, Italy

Francesco Grignani

University of Perugia, Italy

Patrick Mehlen

University of Lyon, Centre Léon Bérard, Lyon, France

Filippo Menolascina

National Cancer Centre, "Giovanni Paolo II", Bari, Italy

Michele Milella

Regina Elena National Cancer Institute, Rome, Italy

Filippo Montemurro

Institute for Cancer Research and Treatment, University of Turin, Candiolo, Italy

Pierlorenzo Pallante

"Federico II" University, Naples, Italy

Pier Paolo Pandolfi

Beth Israel Deaconess Medical Center, Boston, MA, USA



SOCIETA' ITALIANA DI CANCEROLOGIA

53rd Annual Meeting of the Italian Cancer Society

Salvatore Pece

IFOM-IEO Campus, University of Milan, Italy

Letizia Porcelli

National Cancer Centre "Giovanni Paolo II", Bari, Italy

John Quackenbush

Dana-Farber Cancer Institute, Boston, MA, USA

Sabine Riethdorf

University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Giuseppe Saglio

University of Turin, Italy

Massimo Santoro

"Federico II" University, Naples, Italy

Giorgio V. Scagliotti

University of Turin, Italy

Brian Schwartz

ArQule, Woburn, MA, USA

Katia Scotlandi

Orthopaedic Rizzoli Institute, Bologna, Italy

Florin Sirzén

Roche, Basel, Switzerland

Martin Sos

Max-Planck-Institute for Neurological Research, Cologne, Germany

Christos Sotiriou

Breast Cancer Translational Res Lab BCTL, Institute Jules Bordet; Brussels, Belgium

Gabriella Sozzi

IRCCS National Cancer Institute, Milan, Italy

Elda Tagliabue

IRCCS National Cancer Institute, Milan, Italy

Luca Tamagnone

Institute for Cancer Research and Treatment, University of Turin, Candiolo, Italy

Stefania Tommasi

National Cancer Centre "Giovanni Paolo II", Bari, Italy

Ashok Venkitaraman

University of Cambridge, UK

Yosef Yarden

Weizmann Institute, Rehovot, Israel

Programme at a glance

Back to the Future

Translating cancer research
from bedside to bench and back

Turin, 19 – 22 October 2011

Wednesday, October 19th	
14.00	Registration
15.00-16.00	Opening ceremony
16.00-17.00	Opening lecture
17.00-19.00	Lung cancer
19.00	Welcome cocktail

Thursday, October 20th	
08.30-10.15	Breast cancer
10.15-10.45	Coffee break
10.45-12.00	Breast cancer
12.00-13.00	Lunch
13.00-14.00	Poster viewing with the presence of Authors
13.00-14.00	Simposio Agilent Technologies
14.00-17.00	Poster discussion (from 16.00 to 17.00 coffee station)
17.00-19.00	System biology
19.00	Meeting of the SIC young investigators

Friday, October 21st	
08.30-10.30	Hematological oncology
10.30-11.00	Coffee break
11.00-12.00	Award ceremony
12.00-14.00	Lunch and Poster viewing
14.00-15.00	Giorgio Prodi lecture
15.00-16.20	New targets (Joint meeting with Pharma Industry)
16.20-16.45	Coffee break
16.45-17.25	New targets (Joint meeting with Pharma Industry)
17.30-19.00	SIC General Assembly (Board Election)
20.30	Social event (Officine Grandi Riparazioni - Via Paolo Borsellino, 19 - Turin)

Saturday, October 22nd	
08.45-10.45	New players in the field
10.45-11.15	Coffee break
11.15-11.45	New players in the field
11.45-12.45	Closing lecture
12.45-13.00	Closing remarks



SOCIETA' ITALIANA DI CANCEROLOGIA

53rd Annual Meeting of the Italian Cancer Society

Wednesday, October 19th Scientific Programme

14.00	Registration	
15.00 – 16.00	Opening Ceremony Greetings from the Authorities	
16.00 – 17.00	OPENING LECTURE Targeting K-Ras oncogenic signaling in cancer Mariano Barbacid (<i>Madrid, Spain</i>)	
17.00 – 19.00	LUNG CANCER <i>Chairmen: Massimo Aglietta (Turin, Italy), Gabriella Sozzi (Milan, Italy)</i>	
17.00 – 17.30	Molecular targets in lung cancer Giorgio V. Scagliotti (<i>Turin, Italy</i>)	
17.30 – 17.45	Regulatory role of Semaphorin 3A in normal and tumoral lung C. Micucci , S. Orciari, C. Avellini, D. Lucchetti, M. Barbacid, P.G. Pellicci, A. Catalano <i>Department of Clinical and Molecular Science, Marche Polytechnic University, Ancona, Italy</i>	14B
17.45 – 18.15	Cancer genomics for the identification of druggable targets in lung cancer Martin Sos (<i>Cologne, Germany</i>)	
18.15 - 18.30	Prognostic role and biological significance of CD157 in malignant pleural mesothelioma S. Morone , A. Giacomino, R. Parrotta, N. Lo Buono, I. Rapa, L. Righi, M. Volante, E. Ruffini, S. Demichelis, G. Rovere, S. Novello, E. Ortolan, A. Funaro <i>Genetics, Biology and Biochemistry, University of Turin, Turin, Italy</i>	27N
18.30 – 19.00	Cancer predisposition Tommaso Dragani (<i>Milan, Italy</i>)	
19.00	Welcome Cocktail	

- 08.30 – 12.00** **BREAST CANCER**
Chairmen: Maria Flavia Di Renzo (Turin, Italy), Filippo Montemurro (Turin, Italy)
- 08.30 – 09.00 **Stem cells and breast cancer: clinical and pathogenetic implications**
Salvatore Pece (*Milan, Italy*)
- 09.00 – 09.30 **Cancer micrometastasis and circulating tumor cells**
Sabine Riethdorf (*Hamburg, Germany*)
- 09.30 – 09.45 **The p140Cap adaptor protein reverts Her2-induced disruption of epithelial tissue differentiation in breast cancer** **10D**
P. Di Stefano, S. Grasso, S. Aramu, S. Lunardi, D. Repetto, N. Sharma, E. Turco, **P. De Filippi**
Molecular Biotechnology Centre, University of Turin, Turin, Italy
- 09.45 – 10.15 **Genetic signatures in breast cancer**
Christos Sotiriou (*Brussels, Belgium*)
- 10.15 – 10.45 *Coffee break*
- 10.45 – 11.15 **New insights in BRCA1. BRCA2**
Ashok Venkitaraman (*Cambridge, UK*)
- 11.15 – 11.30 **Numb controls mode of division, proliferative rate and tumorigenic potential of mammary stem cells by regulating the Notch and the p53 pathways** **16C**
D. Tosoni, S. Zecchini, M. Cozzoli, S. Pece, P.P. Di Fiore
Molecular Medicine for Care Program, European Institute of Oncology, Milan, Italy
- 11.30 – 12.00 **Resistance to HER2 targeted therapies**
Elda Tagliabue (*Milan, Italy*)
- 12.00 – 13.00 Lunch
- 13.00 – 14.00** **Poster viewing with the presence of Authors**
- 13.00 - 14.00** **Simposio Agilent Technologies**



SALA CAVOUR

14.00 - 17.00

POSTER DISCUSSION

**CANCER STEM CELLS, APOPTOSIS AND CELL CYCLE REGULATION,
SIGNAL TRANSDUCTION AND INTRACELLULAR TRAFFICKING**

Chairmen: Maria Felice Brizzi (Turin, Italy), Katia Scotlandi (Bologna, Italy)

Twist1 interacts with and promotes p53 degradation

8A

S. Sessa, E. Tonin, S. Piccinin, F. Pivetta, C. Rosano, R. Maestro

Unit of Experimental Oncology 1, CRO National Cancer Institute, Aviano (PN)

Twist1 plays a pleiotropic role in determining the anaplastic thyroid cancer phenotype

3P

G. Di Maro, P. Salerno, T.C. Bencivenga, F. Orlandella, R. Maestro, A. Fusco, M. Santoro, G. Salvatore

Department of Biology and Cellular and Molecular Pathology, NCR Institute of Experimental Endocrinology and Oncology, "Federico II" University, Naples, Italy

Co-expression of CD133 and CXCR4 defines the subset of highly metastatic lung cancer initiating cells

1C

G. Bertolini, I. Roato, M. Moro, L. D'Amico, M. Tortoreto, R. Caserini, U. Pastorino, L. Roz, R. Ferracini, G. Sozzi

IRCCS National Cancer Institute, Milan, Italy

Quiescence-keeper microRNAs dampen oncogene-induced transcriptional reprogramming

4E

F. Nicassio

Department of Experimental Oncology, IEO - European Institute of Oncology, Milan, Italy

A new CDK-independent function of p27kip1 in the control of cell proliferation

10P

I. Pellizzari, L. Fabris, S. Berton, I. Segatto, J. Armenia, B. Belletti, G. Baldassarre

Unit of Experimental Oncology 2, CRO National Cancer Institute, Aviano (PN)

Constitutive activation of the ETS-1-miR-222 circuitry in metastatic melanoma

8P

G. Mattia, M. C. Errico, F. Felicetti, M. Petrini, L. Bottero, A. Lustrì, N. Felli, M. P. Colombo, **A. Carè**

Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore Sanità, Rome, Italy

Ring ligase praja2 inhibits tumor suppressor Hippo pathway and promotes glioblastoma growth

7P

L. Lignitto, A. Feliciello

Department of Biology and Cellular and Molecular Pathology, NCR Institute of Experimental Endocrinology and Oncology, "Federico II" University, Naples, Italy

CANCER GENETICS, CONTROL OF GENE EXPRESSION

Chairmen: Amedeo Columbano (Cagliari, Italy), Pierlorenzo Pallante (Naples, Italy)

Identification of familial neuroblastoma associated genes by whole exome sequencing **10B**

L. Longo, M. De Mariano, F. Del Grosso, E. Stupka, F. Lescai, M. Chierici, M. Roncador, C. Furlanello, G. P. Tonini
Italian Neuroblastoma Foundation, Genoa, Italy and Translational Oncopathology , National Cancer Research Institute (IST), Genoa, Italy

Increased expression of HINT1 inhibits proliferation and tumorigenesis of melanoma cells by negatively modulating key oncogenic pathways **8B**

G. Genovese, H. Li, A. Cittadini, **A. Sgambato**
"Giovanni XXIII" Cancer Research Center, Catholic University of Sacred Heart, Rome, Italy

Mixed lineage kinase 4 (MLK4) is mutationally activated in colorectal cancers and represents a novel target in RAS-driven tumors **13B**

M. Martini, S. Lamba, M. Russo, E. Vitiello, S. Shirasawa, A. Marchetti, A. Bardelli
Department of Oncological Science, Institute for Cancer Research and Treatment, Candiolo, Italy

Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK-1 dysregulation is an early event maintained along tumor progression **19B**

A. Petrelli, A. Perra, K. Schernhuber, A. Salvi, C. Migliore, E. Ghiso, A. Benetti, S. Barlati, G.M. Ledda-Columbano, N.S. Portolani, G. De Petro, A. Columbano, S. Giordano
Department of Oncological Science, Institute for Cancer Research and Treatment, Candiolo, Italy

Hox genes methylation status analysis in patients with hereditary breast cancer **11F**

B. Pilato, **S. De Summa**, K. Danza, R. Lambo, A. Paradiso, S. Tommasi
Molecular Genetics Laboratory, National Cancer Centre, Bari, Italy

CBX7 is a tumour suppressor gene in lung carcinogenesis inhibiting Cyclin E expression **7F**

F. Forzati, A. Federico, P. Pallante, F. Esposito, R. Sepe, G. Troncone, C. Arra, M. Fedele, A. Fusco
NCR Institute of Experimental Endocrinology and Oncology, Naples, Italy

MIR-342 modulates ID4 expression in breast cancer **4F**

E. Crippa, A. Fiorino, E. Marchesi, M.A. Pierotti, M. Gariboldi
Department of Experimental Oncology, IRCCS National Cancer Institute, Milan, Italy



SALA EINAUDI

14.00 - 17.00

POSTER DISCUSSION

**DRUG RESISTANCE, MOLECULAR MARKERS OF DIAGNOSIS,
PROGNOSIS AND RESPONSE TO TREATMENT**

Chairmen: Anna Bagnato (Rome, Italy), Federica Di Nicolantonio (Turin, Italy)

Comparing different agents anti-IGF-1R to identify common and distinctive mechanisms of resistance in Ewing's sarcoma 7H

C. Garofalo, C. Mancarella, A. Grilli, M.T. Marino, P. Picci, K. Scotlandi

CRS Development of Biomolecular Therapies, Experimental Oncology Laboratory, Rizzoli Orthopaedic Institute, Bologna, Italy

KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors (GIST) 12H

C. Miranda, M. Nucifora, F. Molinari, E. Conca, M.C. Anania, A. Bordoni, P. Saletti, L. Mazzucchell, S. Pilotti, M.A. Pierotti, E. Tamborini, A. Greco, M. Frattini

Department of Experimental Oncology and Molecular Medicine, IRCCS National Cancer Institute, Milan, Italy

Mechanisms of resistance of thyroid cancer cells to BRAF V600E ATP competitive inhibitor 14H

M. Muthu, M.D. Castellone, G. Salvatore, B. Lestini, F. Su, C. Migliore, S. Giordano, M. Santoro

Department of Biology and Cellular and Molecular Pathology, NCR Institute of Experimental Endocrinology and Oncology, "Federico II" University, Naples, Italy

Response to treatment with chemical and biological inhibitors of c-MET mutated forms 1H

M.M. Angioni, S. Corso, S. Giordano

Department of Oncological Science, Institute for Cancer Research and Treatment, Candiolo, Italy

Anti-VEGF treatment resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype 3H

C. Carbone, T. Moccia, C. Zhu, G. Paradiso, A. Budillon, P. J. Chiao, J.L. Abbruzzese, **D. Melisi**

Experimental Pharmacology Unit, National Cancer Institute "G. Pascale", Naples, Italy

Gene expression profile of paired primary and relapse epithelial ovarian cancer results in modulation of the epithelial to mesenchymal transition program 33N

M. Romano, R. Fruscio, I. Fuso Nerini, L. Beltrame, L. Clivio, G. Chiorino, L. Porcu, E. Erba, S. Marchini, M. Betti, S. Di Giandomenico, D. Cavalieri, M. D'Incalci

Department of Oncology, "Mario Negri" Institute for Pharmacological Research, Milan, Italy

Sources of microRNA detected in plasma samples of non-small-cell-lung-cancer patients 7N

M. Boeri, L. Roz, G. Sozzi

Tumoral Genomics, IRCCS National Cancer Institute, Milan, Italy

CELL INVASION AND METASTASIS, TUMOR IMMUNOLOGY AND TUMOR MICROENVIRONMENT

Chairmen: Letizia Porcelli (Bari, Italy), Luca Tamagnone (Turin, Italy)

β -arrestin-1 as a nuclear transcriptional regulator of endothelin a receptor signalling in epithelial to mesenchymal transition and chemoresistance **19D**

L. Rosanò, R. Cianfrocca, P. Tocci, V. Di Castro, F. Spinella, E. Salvati, A. Biroccio, P.G. Natali, A. Bagnato
Laboratories of Molecular Pathology, "Regina Elena" National Cancer Institute, Rome, Italy

Chemotherapy to counteract tumor metastasis spread after inhibition of angiogenesis **20D**

A. Rovida, M. Cesca, V. Scarlato, V. Castiglioni, R. Giavazzi
Laboratory of Biology and Treatment of Metastasis, Department of Oncology, "Mario Negri" Institute for Pharmacological Research, Milan, Italy

TNF-alpha promotes invasive growth via the MET-SNAIL pathway **4D**

V. Bigatto, F. De Bacco, E. Casanova, P.M. Comoglio, C. Boccaccio
Institute for Cancer Research and Treatment, University of Turin, Candiolo, Italy

T cell activation and maturation at tumor site associated with objective response to Ipilimumab in metastatic melanoma **10R**

R. Mortarini, M. Del Vecchio, G. Tragni, L. Di Guardo, I. Bersani, G. Di Tolla, A. Agustoni, V. Colonna, J.S. Weber, A. Anichini
Department of Experimental Oncology and Molecular Medicine, IRCCS National Cancer Institute, Milan, Italy

Semaphorin 3A blocks tumor invasiveness and metastases formation induced by antiangiogenic therapy by overcoming cancer hypoxia **16S**

F. Maione, S. Capano, D. Regano, L. Zentilin, M. Giacca, F. Bussolino, G. Serini, E. Giraudo
Laboratory of Transgenic Mouse Models, Department of Oncological Science, University of Turin, Institute for Cancer Research and Treatment, University of Turin, Candiolo, Italy

Endothelial progenitor cells (EPCs) characterization in adult human adipose tissue **1S**

C. Aldeni, J. Quarna, G. Gregato, A. Calleri, C. Corsini, P. Marighetti, I. Martin Padura, P. Mancuso V. Lohsiriwat, J.Y. Petit, F. Bertolini
Laboratory of Hemato-Oncology and Division of Plastic Surgery, European Institute of Oncology, Milan, Italy

Human arterial ring assay: an ex vivo sprouting angiogenesis model for anti-angiogenic drug screening and functional genomic studies **30S**

G. Seano, R. Sessa, P.A. Gagliardi, L. Di Blasio, F. Bussolino, L. Primo
Department of Oncological Science, University of Turin, Institute for Cancer Research and Treatment, University of Turin, Candiolo, Italy

16.00 – 17.00 Coffee station



17.00 – 19.00

SYSTEM BIOLOGY

Chairmen: Federico Bussolino (Turin, Italy), Stefania Tommasi (Bari, Italy)

17.00 – 17.30

Driving discovery through data integration and analysis

John Quackenbush (Boston, USA)

17.30 – 17.45

Genome sequencing reveals the proliferation dynamics of colorectal adenomas

*A. De Grassi, F. Iannelli, V. Melocchi, A. Viel, G. Basso, L. Laghi, M. Caselle, F.D. Ciccarelli
European Institute of Oncology, Milan, Italy*

4Q

17.45 – 18.15

**EGFR and HER2: lessons in biological complexity and opportunities
for cancer therapies**

Yosef Yarden (Rehovot, Israel) - Sponsored by EACR

18.15-18.30

**Genome-Wide analysis of mixed microRNA – transcription factor feed-forward regulatory
circuits in human**

*D. Cora, O. Friard, M. El Baroudi, A. Re, D. Taverna, M. De Bortoli, M. Caselle
Laboratory of System Biology, Institute for Cancer Research and Treatment, Candiolo, Italy*

3Q

18.30 – 19.00

**Optimal experimental design in cancer systems biology:
a control theoretic point of view**

Filippo Menolascina (Bari, Italy)

19.00

Meeting of the SIC young investigators

- 08.30 – 10.30** **HEMATOLOGICAL ONCOLOGY**
Chairmen: Riccardo Dolcetti (Aviano PN, Italy), Raffaella Giavazzi (Milan, Italy)
- 08.30 – 09.00 **Epigenetic and hematological oncology**
Francesco Grignani (*Perugia, Italy*)
- 09.00 – 09.15 **Treatment of a new model of chronic Lymphocytic Leukemia using Chlorambucil/Hydroxychloroquine-loaded anti-CD20 nanoparticles** **22L**
N. Mezzaroba, F. Bravin, S. Zorzet, E. Mansilla, M. Calvaruso, C. Tripodo, L. Nunez, F. Tedesco, D. Sblattero, **P. Macor**
Life Sciences, University of Trieste, Trieste, Italy
- 09.15 – 09.45 **Targeted therapies in myeloma**
Mario Boccadoro (*Turin, Italy*)
- 09.45 – 10.00 **Serological identification of HSP105 as a novel non-Hodgkin lymphoma associated antigen** **30L**
S.M. Pupa, R. Zappasodi, G.C. Ghedini, I. Bongarzone, L. Castagnoli, A.D. Cabras, C. Tripodo, A. Messina, M. Tortoreto, A.M. Gianni, M. Di Nicola
Molecular Targeting Unit, IRCCS National Cancer Institute, Milan, Italy
- 10.00 – 10.30 **Targeted therapies in CML**
Giuseppe Saglio (*Turin, Italy*)
- 10.30 – 11.00 *Coffee break*
- 11.00 – 12.00** **Award Ceremony**
- Pisa Cancer Association “Piero Trivella” Award for the best poster
 - EACR Award for the best poster
 - “Elena Cappannini” Award for the best 2010 publication
 - “Pezcoller Foundation” scholarship Award, **G. Bernardi, President**
- 12.00 – 14.00 Lunch and poster viewing



**53rd Annual Meeting of the
Italian Cancer Society**

**Friday, October 21st
Scientific Programme**

14.00 – 15.00

Giorgio Prodi Lecture

The past as a platform for new DNA cancer vaccines

Guido Forni (*Turin, Italy*)

15.00 – 17.25

NEW TARGETS (Joint meeting with Pharma Industry)

Chairmen: Alfredo Budillon (Naples, Italy), Maurizio D'Incalci (Milan, Italy)

15.00 – 15.25

Molecular targeting of RET kinase for thyroid cancer treatment

Massimo Santoro (*Naples, Italy*)

15.25 – 15.50

Targeting the MET oncogene and the invasive growth program

Paolo M. Comoglio (*Turin, Italy*)

15.50 – 16.05

**Discovery and Development of Tivantinib,
Non-ATP-Competitive Inhibitor Targeting MET Tyrosine Kinase
for the Treatment of Advanced Cancers**

ArQule, Brian Schwartz (*Woburn, MA, USA*)

16.05 – 16.20

The development of an anti-CMET monovalent antibody

Roche, Florin Sirzén (*Basel, Switzerland*)

16.20 – 16.45

Coffee Break

16.45 – 17.10

Rational targeting of the RAF/MEK/ERK pathway at multiple levels

Michele Milella (*Rome, Italy*)

17.10 – 17.25

The development of a selective V600mutated BRAF inhibitor

Roche, Florin Sirzén (*Basel, Switzerland*)

17.30 – 19.00

SIC General Assembly (Board Election)

20.30

Social Event

- 08.45 – 11.45** **NEW PLAYERS IN THE FIELD**
Chairmen: Adriana Albini (Milan, Italy), Donatella Del Bufalo (Rome, Italy)
- 08.45 – 09.15 **The Hippo-YAP pathway in organ size control and tumorigenesis**
Giovanni Blandino (*Rome, Italy*)
- 09.15 – 09.30 **Selective targeting of Notch-1 in T-Acute Lymphoblastic Leukemia** **19L**
S. Indraccolo, S. Minuzzo, V. Agnusdei, T. Hoey, C. Frasson, E. Seganfredo, E. Giarin, G. Basso, V. Tosello, A.A. Ferrando, M. Ponzoni, A. Amadori
Istituto Oncologico Veneto IRCCS, Padua, Italy
- 09.30 – 10.00 **Dependence receptors in cancer**
Patrick Mehlen (*Lyon, France*)
- 10.00 – 10.15 **Antitumor activity of gold (III) dithiocarbamate-peptide in prostate cancer cells and xenografts** **8L**
M. Celegato, D. Fregona, M. Mongiat, L. Ronconi, C. Borghese, V. Canzonieri, N. Casagrande, A. Colombatti, D. Aldinucci
Unit of Experimental Oncology 2, CRO National Cancer Institute, Aviano (PN)
- 10.15 – 10.45 **Micro RNA and cancer**
George Adrian Calin (*Houston, USA*)
- 10.45 – 11.15 *Coffee break*
- 11.15 – 11.45 **Epigenetic mechanisms in hereditary colorectal cancer**
Adrianus Henricus Maria Geurts van Kessel (*Nijmegen, The Netherlands*) –
Joint invitation SIGU-SIC
- 11.45 – 12.45** **CLOSING LECTURE**
Deconstructing the molecular genetics of human cancer and its therapeutic implications
Pier Paolo Pandolfi (*Boston, USA*)
- 12.45 – 13.00 Closing remarks



SOCIETA' ITALIANA DI CANCEROLOGIA

53rd Annual Meeting of the Italian Cancer Society

Scientific Information

ITALIAN CME CREDITS

No. 6 Italian Ministry of Health CME (Continuing Medical Education) credits have been assigned for Biologists Medical Surgeons (Haematology, Medical Genetics, Oncology, Pharmacology and Clinical Toxicology, Clinical Pathology, Morbid Anatomy), Chemists (Analytical Chemistry), Physicists (Health Physics) and Veterinary Surgeons

AUDIOVISUAL INSTRUCTIONS

A Multimedia Slide Centre is located in the Meeting Venue.

ONLY PC DATA PROJECTION IS AVAILABLE DURING THE MEETING.

Each room is provided with a laptop. Therefore the use of your personal laptop is not allowed.

Should speakers have their personal laptop or CD Rom or USB key, they are kindly requested to go to the Multimedia Slide Centre to have their presentation copied. The presentation will be then forwarded through a LAN network from the Multimedia Slide Centre directly to the computer in the presentation room.

We kindly recommend speakers to contact the Multimedia Slide Centre the day before their presentation. If this is not possible, please deliver your PowerPoint presentation 1 hour before the session on CD-ROM or USB Key.

PRIZES

“Piero Trivella” and “EACR” Awards for the best posters

Travel Grants

“Elena Cappannini” Prize to the best 2010 publication as first author in innovative approaches for cancer treatments

“Pezcoller Foundation” scholarship Award

All prizes will be awarded, on the basis of a merit ranking, on Friday 21 October, during the Award Ceremony.

WITH THE PATRONAGE OF



General Information

Back to the Future

Translating cancer research
from bedside to bench and back

Turin, 19 – 22 October 2011

DATES

Turin, Wednesday 19 – Saturday 22, October 2011

MEETING VENUE

Torino Incontra Conference Centre

Via Nino Costa, 8 – 10123 Turin - Ph. +39 011 557 68 00 – Fax +39 011 557 68 09

Web site: www.torinoincontro.org

SIC SECRETARIAT

Società Italiana di Cancerologia

Via G. Venezian, 1 – 20133 Milan - Ph. +39 02 2666895 – Fax +39 02 2664342

E-mail: sic@istitutotumori.mi.it – Web site: www.cancerologia.it

ORGANIZING SECRETARIAT



Adria Congrex
advanced congress experience

Via Sassonia, 30 – 47922 Rimini RN - Ph. +39 0541 305811 - Fax +39 0541 305842

E-mail: sic2011@adriacongrex.it – Web site: www.adriacongrex.it/sic2011

LANGUAGE

The official language of the Meeting is English. Simultaneous translation will not be provided.

BADGES

Participants are kindly requested to wear their badge throughout the Meeting.

CERTIFICATES OF ATTENDANCE

Certificate of attendance is issued on request to all registered participants at the end of the Meeting.

EXHIBITION AND SPONSORSHIP

A technical, pharmaceutical and publication exhibition will take place in the Meeting Venue throughout the scientific works.

REGISTRATION FEES

	On-site registration
SIC MEMBER (*)	€ 430,00
NON SIC MEMBER (**)	€ 534,00
SIC MEMBER UNDER 35 (*)	€ 280,00
NON SIC MEMBER UNDER 35 (**)	€ 351,00

Daily registration October 20 and 21	On-site registration	Daily registration October 19 and 22	On-site registration
SIC MEMBER (*)	€ 150,00	SIC MEMBER (*)	€ 75,00
NON SIC MEMBER (**)	€ 180,00	NON SIC MEMBER (**)	€ 90,00
SIC MEMBER UNDER 35 (*)	€ 100,00	SIC MEMBER UNDER 35 (*)	€ 50,00
NON SIC MEMBER UNDER 35 (**)	€ 120,00	NON SIC MEMBER UNDER 35 (**)	€ 60,00

(*) VAT non applicable as for the law ex Art. 4 DPR 633/72; (**) VAT 21% included

The registration fee entitles delegates to the following:

- entry to all Scientific Sessions and Exhibition Area
- congress kit
- CME credits
- scientific material
- certificate of attendance
- admission to the Opening Ceremony and Welcome Cocktail, coffee breaks, light buffet lunches and social event

CANCELLATION

In case of cancellation reimbursement will not be done.

INSURANCE

Registration fee does not include insurance of any kind. The Congress Organizers will not be responsible for any participant failing or damages. Any type of insurance should be purchased by congress participants on their own.



SOCIETA' ITALIANA DI CANCEROLOGIA

53rd Annual Meeting of the Italian Cancer Society

HOW TO REACH THE MEETING VENUE



- 1 PORTA PALATINA
- 2 DUOMO - CAPPELLA SINDONE
- 3 PALAZZO REALE
- 4 GIARDINI REALI
- 5 ARMERIA REALE
- 6 PALAZZO MADAMA
- 7 TEATRO REGIO
- 8 MOLE ANTONELLIANA
- 9 MUSEO NAZIONALE DEL CINEMA
- 10 GRAN MADRE DI DIO
- 11 PALAZZO CARIGNANO
- 12 MUSEO EGIZIO
- 13 GALLERIA SABAUDA
- 14 MUSEO DEL RISORGIMENTO
- 15 ACCADEMIA DELLE SCIENZE
- 16 PINACOTECA ACCADEMIA ALBERTINA
- 17 MONTE DEI CAPPUCCINI
- 18 MONUMENTO E. FILIBERTO
- 19 PALAZZO BRICHERASIO
- 20 MUSEO SCIENZE NATURALI
- 21 CONSERVATORIO
- 22 PIAZZA CARLO FELICE
- 23 STAZIONE PORTA NUOVA
- 24 PARCO DEL VALENTINO

Torino Incontra Conference Centre

The Torino Incontra Conference Centre is located in the city centre. Please find here below some useful information.

From Caselle international airport

By car: the airport is 16 kilometres from Turin city centre, approximately 30 minutes by car.

By train: for the convenience of airport users, a railway station has been built in the immediate vicinity of the terminal. The railway service is operated by GTT.

By bus: the SADEM bus service links the airport with Turin city centre in around 40 minutes.

By taxi: the taxi rank can be found to the left of the Arrival lounge exit. The journey to Turin town centre takes around 30 minutes.

From Porta Nuova railway station

After going out from the station, turn right to Corso Vittorio Emanuele and walk until the crossing with Via San Francesco da Paola. Turn left and walk until Piazza Valdo Fusi, on your left you will find the Torino Incontra Conference Centre. It will take 10 minutes.

From Porta Susa railway station

After going out from the station take Via Cernaia and walk until Piazza Solferino. Go on to Via Santa Teresa until Piazza San Carlo. Go on to Via Maria Vittoria until the crossing with Via San Francesco da Paola. Turn right and walk until Piazza Valdo Fusi, on your right you will find the Torino Incontra Conference Centre. It will take 30 minutes.



SOCIETA' ITALIANA DI CANCEROLOGIA

53rd Annual Meeting of the
Italian Cancer Society

Save the date!

54th Meeting of the Italian Cancer Society

MISSION [IM]POSSIBLE

*understanding cancer-host dialogues
for personalized cancer medicine*

Bologna, 1-4 October 2012

Scientific Coordinators

Katia Scotlandi (Rizzoli Institute, Bologna)

Guido Biasco (University of Bologna)

Local Scientific Committee

Michele Baccarani (University of Bologna)

Lucio Cocco (University of Bologna)

Sandro Grilli (University of Bologna)

Pier-Luigi Lollini (University of Bologna)

Andrea Pession (University of Bologna)

Piero Picci (Rizzoli Institute, Bologna)

Stefano Pileri (University of Bologna)

Organizing Secretariat

STUDIO ER CONGRESSI

TRIUMPH GROUP

Via Marconi, 36 - 40122 Bologna Italy

Phone: +39 051 4210559 - Fax: +39 051 4210174

E-mail: ercongressi@triumphgroup.it

Web site: www.ercongressi.it

Back to the Future

Translating cancer research
from bedside to bench and back

Turin, 19 – 22 October 2011

A grateful thank to:



We Innovate Healthcare





SOCIETÀ ITALIANA DI CANCEROLOGIA

53rd Annual Meeting of the
Italian Cancer Society

Back to the Future

Translating cancer research
from bedside to bench and back

Turin, 19 – 22 October 2011